BID Polyclonal Antibody

BID encodes a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. BH3-interacting domain death agonist is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves BH3-interacting domain death agonist, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Multiple alternatively spliced transcript variants have been found, but the full-length nature of some variants has not been defined.

The BID Polyclonal Antibody is a highly specific and sensitive immunological tool designed for the detection and quantification of BID protein expression in various biological samples. This antibody is produced by immunizing animals with a synthetic peptide corresponding to a specific region of the BID protein sequence.

The BID Polyclonal Antibody exhibits exceptional affinity and selectivity towards BID protein, enabling accurate and reliable results in a wide range of applications, including Western blotting, immunohistochemistry, and immunofluorescence. Its superior sensitivity allows for the detection of even low levels of BID protein expression, ensuring precise and reproducible data analysis.

This antibody is manufactured under stringent quality control measures to ensure batch-to-batch consistency and optimal performance. It has been extensively validated in various experimental settings, demonstrating its robustness and reliability. The BID Polyclonal Antibody is suitable for use in both research and clinical laboratories, providing valuable insights into the role of BID protein in cellular processes and disease pathogenesis.

With its exceptional specificity, sensitivity, and reliability, the BID Polyclonal Antibody is an indispensable tool for researchers and scientists seeking to explore the intricate mechanisms involving BID protein. Its high-quality performance and consistent results make it an ideal choice for a wide range of applications, facilitating breakthrough discoveries and advancements in the field of biomedical research.